Stock LIGAND PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Ligand Pharmaceuticals Inc. OTC Bulletin Board

Equities

US53220K1815

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Ligand Pharmaceuticals Inc.
Jun. 18 Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals MT
Jun. 18 Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE for Adults
AQ
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals
MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
BU
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults
CI
Ligand Pharmaceuticals Incorporated : First Quarter 2024 Presentation
PU
Ligand to Participate in Upcoming Investor Conferences
BU
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing
MT
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views
MT
Ligand: Q1 Earnings Snapshot
AQ
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M
MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83
MT
Ligand Reports First Quarter 2024 Financial Results
BU
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024
CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
MT
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
BU
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LGND Stock
  4. Stock
  5. News Ligand Pharmaceuticals Inc.